Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer  by Yang, Kai-Fu et al.
lable at ScienceDirect
Urological Science 26 (2015) 271e276Contents lists avaiUrological Science
journal homepage: www.urol-sci .comOriginal articlePrediction for survival following docetaxel-based chemotherapy in
Taiwanese men with castration-resistant metastatic prostate cancer
Kai-Fu Yang a, Hsiang-Ying Lee a, Wen-Jeng Wu a, b, c, Chun-Hsiung Huang a, c,
Yii-Her Chou a, c, Chun-Nung Huang a, c, Yung-Chin Lee a, c, Shu-Pin Huang a, c, *
a Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
b Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan
c Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwana r t i c l e i n f o
Article history:
Received 17 April 2014
Received in revised form
31 March 2015
Accepted 31 March 2015
Available online 8 May 2015
Keywords:
castration-resistant metastatic prostate
cancer
docetaxel* Corresponding author. Department of Urology, Co
Medical University, Number 100, Shih-Chuan 1st Road
E-mail address: shpihu@yahoo.com.tw (S.-P. Huan
http://dx.doi.org/10.1016/j.urols.2015.03.005
1879-5226/Copyright © 2016, Taiwan Urological Ass
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Introduction: Docetaxel-based chemotherapy has been demonstrated to improve survival in patients
with metastatic castration-resistant prostate cancer (mCRPC). The aim of this study is to analyze the
possible prognostic factors associated with survival and to attract physicians' attention to high-risk
patients.
Material and methods: Thirty-nine consecutive patients with mCRPC who received docetaxel-based
chemotherapy between July 2007 and November 2013 were enrolled in this study. The KaplaneMeier
curve was used to assess the association between prostate-speciﬁc antigen (PSA) response (deﬁned as
PSA level decreases  50%), and overall survival and cancer-speciﬁc survival. Cox regression analysis was
performed to identify the independent signiﬁcant predictors of overall survival and cancer-speciﬁc
survival.
Results: Twenty-one of the 39 patients (54%) experienced PSA response and the median overall survival
was 13.51 months (range, 3e43 months). Patients with PSA response had longer time to PSA nadir level
compared with patients without PSA response (p ¼ 0.010). PSA response was an independent factor of
overall survival and cancer-speciﬁc survival from Cox regression analysis (p ¼ 0.014 and p ¼ 0.05,
respectively). In both univariate and multivariate analysis, cycles of chemotherapy, time to PSA nadir, and
time to PSA progression were signiﬁcant predictors for overall survival.
Conclusion: The present study showed that PSA response demonstrated signiﬁcance as a predictor for
clinical outcome. However, Charlson comorbidity index (CCI) is not related to survival. A further pro-
spective analysis is warranted.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the secondmost commonmalignancy in
men worldwide and is the sixth leading cause of death with
258,000 deaths annually.1 Although the incidence rate and mor-
tality rate of PCa in Asia are lower than in Western societies, it has
been increasing in Asian men including Taiwanese men within
recent years.2 For localized prostate cancer, treatment including
radiotherapy or surgery can control the tumor burden efﬁciently
and present excellent disease outcome. However, for some it canllege of Medicine, Kaohsiung
, Kaohsiung City 807, Taiwan.
g).
ociation. Published by Elsevier Tabecome an advanced or metastatic disease.3 For these patients,
androgen deprivation therapy (ADT) is the initial choice of treat-
ment when PCa is under a hormone sensitive state. The tumor can
regress while serum prostate-speciﬁc antigen (PSA) will decline
after ADT, which also alleviates symptoms of disease such as bone
pain.4 Nevertheless, metastatic PCa will become resistant to ADT
and be renamed to metastatic castration-resistant prostate cancer
(mCRPC) after an average of 2 years.5
Since the two large completed Phase III randomized control
trials of SWOG 99-166 and TAX 3277 demonstrated the role of
chemotherapy in mCRPC in 2004, docetaxel-based chemotherapy
has been regarded as the main system of management that pre-
sents signiﬁcant survival beneﬁts. In the past 5 years, several novel
treatments have been studied in Phase III clinical trials for patients
not suitable for or resistant to docetaxel. Although it needs furtheriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Characteristics of the patients.
Characteristics
Number 39
Age (y)
72.08 ± 9.31 (54e88)
Number of cycles 6.72 ± 2.77 (2e14)
Serum PSA (ng/mL) 386.82 ± 723.40 (5.28e3855.51)
Hgb (g/dL) 10.89 ± 1.66 (7.50e13.80)
Metastatic site(s)
Bone 36 (92)
Lymph node 17 (43.6)
Viscera 4 (10)
Lung 1 (2.5)
Liver 2 (5)
Brain 1 (2.5)
PSA response 21 (54)
PSA never decrease 6 (15)
PSA nadir (ng/mL) 88.33 ± 112.00 (0.54e448.59)
Time to PSA nadir (mo) 4.30 ± 3.54 (0.50e13.00)
Time to PSA progression (m) 5.14 ± 5.39 (0.00e23.00)
Survival time after chemotherapy (m) 13.51 ± 9.69 (3e43)
CCI scores (scores) 9.62 ± 1.84 (7e17)
Death 22 (56)
Data are presented as n (%) or median ± SD.
CCI ¼ Charlson comorbidity index; Hbg ¼ hemoglobulin; PSA ¼ prostate-speciﬁc
antigen.
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ment option for mCRPC patients.8
Many previous studies have demonstrated that reductions in
PSA of at least 50% from baseline can present improved survival and
is considered to be a marker of response in patients after receiving
systemic therapy.9 The purpose of this study was to evaluate the
inﬂuence of PSA kinetics in survival outcome and to identify other
possible prognostic factors including Charlson comorbidity index
(CCI) in Taiwanese men with mCRPC.
2. Materials and methods
The present study included 39 consecutive patients withmCRPC
who received docetaxel-based chemotherapy between July 2007
and November 2013 in Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan. All patients were conﬁrmed as having prostate
adenocarcinoma histologically with metastasis upon imaging
including computed tomography, magnetic resonance imaging, or
bone scans, and disease progression despite androgen deprivation
therapy with no previous treatment of chemotherapy. Three
sequential increases in serum PSA level with castration levels of
serum testosterone (< 50 ng dL1) was recognized as mCRPC. This
study was approved by the Institutional Review Board of our
institution.
The therapeutic schedule in our institution consisted of doce-
taxel 70 mg/m2 over 60 minutes through intravenous infusion on a
28-day cycle, plus oral prednisolone (5 mg) twice daily for 5 days
(Days 1e5). We retrospectively evaluated data with various pa-
rameters including patient characteristics during chemotherapy
(age, serum PSA level, hemoglobulin level, serum PSA nadir, time to
PSA nadir, time to progression, cycles of chemotherapy, and
Charlson scores). After the beginning every cycle of chemotherapy,
serum PSA level was checked combined with complete blood
count, and renal and liver functions. PSA response was deﬁned as a
reduction of at least 50% from the baseline levels for at least 4
weeks. PSA nadir is the lowest point of serum PSA level, and the
time to PSA nadir means the duration from the initial chemo-
therapy to PSA nadir level. The deﬁnition of PSA progression is
more than a 50% rise from the PSA nadir and an elevation in the
absolute PSA level by at least 5 ng/mL conﬁrmed after at least 1
week.10 The time to PSA progression was calculated between
chemotherapy initiation and PSA progression. The Charlson scores
were calculated according to the Charlson comorbidity index (CCI),
where weighted scores of 19 comorbidities equal to 1, 2, 3, and 6
based on the severity of the condition.11 The overall survival was
deﬁned as the interval from the ﬁrst docetaxel administration to
the date of death.
After dividing patients into PSA response and no response, The
Student t test was used to compare continuous variables. By using
the KaplaneMeier method, overall survival and prostate-speciﬁc
survival probabilities were analyzed and compared between the
two groups using the log-rank test. The related factors to overall
survival were established by univariate and multivariate analyses
using Cox regression hazard regression models. Because the num-
ber of cases is limited, candidate variables were selected from
univariate analysis within p < 0.1, then multivariate analysis was
calculated with forward selection. A p value <0.05 was considered
statistically signiﬁcant. All statistical tests were performed using
SPSS software version 19 (SPSS Inc., Chicago, IL, USA).
3. Results
The characteristics and treatment response of the 39 patients
are summarized in Table 1. The median age in the initial chemo-
therapy was 72 years (range, 54e88 years) and the median numberof cycles patients received was six, ranging from two cycles to 14
cycles. During follow-up, 22 of the 39 patients (56%) died. At the
start of docetaxel chemotherapy, the median serum PSA level was
386.82 ng/mL (range, 5.28e3855.51 ng/mL) and the hemoglobulin
concentration was 10.89 g/dL (range, 7.50e13.80 g/dL). Among
eligible patients themedian Charlson scores, whichwere calculated
according to their comorbidity condition, was 9.62 points (range,
7e17 points). All patients had metastatic disease and the most
common metastatic site of all patients was bone, then subse-
quently, lymph nodes. During courses of chemotherapy, themedian
PSA nadir level and themedian time to PSA nadir were 88.33 ng/mL
(range, 0.54e448.59 ng/mL) and 4.30 months (range, 0.5e13
months) respectively. Twenty-one of the 39 patients (54%) expe-
rienced PSA response; however, six patients still presented PSA
rising even after receiving chemotherapy. The median overall sur-
vival was 13.51 months (range, 3e43 months). Median time from
treatment initiation to PSA progression was 5.14 months (range,
0e23 months).
After dividing patients into PSA response and no response
groups, we analyzed the possible predictors for PSA response in
Table 2. A signiﬁcant difference in the PSA response in favor of the
longer time to PSA nadir level was noted (p ¼ 0.010). The receiver-
operating characteristic curve of the time to PSA nadir to PSA
response is in Fig. 1 and the cut-off value to predict PSA response is
1.5 months (sensitivity: 95%, speciﬁcity: 50%). KaplaneMeier
analysis, as shown in Figs. 2 and 3, demonstrated that PSA response
is a signiﬁcant factor for longer overall survival and cancer-speciﬁc
survival (p ¼ 0.014 and p ¼ 0.05, respectively). From the results of
univariate and multivariate analyses since the beginning of
chemotherapy in Tables 3 and 4, cycles of chemotherapy, time to
PSA nadir level, and time to PSA progression were independent
predictors of overall and cancer-speciﬁc survival with all at p< 0.05.4. Discussion
As the high incidence of PCa in the world is noted and the risk of
progression to invasive PCa increases with age, many studies are
dedicated to unveiling relevant knowledge of PCa in various ways.
Since the validated evidence of the screening test for PSA level,
Table 2
Association of factors between PSA response and no response.
PSA response (n ¼ 21) PSA no response (n ¼ 18) p
Age (y) 71.48 ± 9.26 72.78 ± 9.59 0.669
Hgb (g/dL) 10.52 ± 1.46 11.32 ± 1.80 0.133
PSA level (ng/mL) 577.98 ± 937.24 163.79 ± 196.24 0.061
PSA nadir (ng/mL) 79.00 ± 98.97 104.64 ± 135.02 0.536
Time to PSA nadir (m) 5.33 ± 3.80 2.50 ± 2.14 0.010*
Number of cycles 7.29 ± 3.07 6.06 ± 2.29 0.170
Time to PSA progression (m) 5.31 ± 5.85 4.83 ± 4.71 0.812
CCI scores 9.67 ± 2.20 9.56 ± 1.38 0.854
Data are presented as mean ± SD.
* p < 0.05.
CCI ¼ Charlson comorbidity index; Hgb ¼ hemoglobulin; PSA ¼ prostate-speciﬁc antigen.
Fig. 1. ROC curve of the time to prostate-speciﬁc antigen (PSA) nadir to PSA response.
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have declined due to early detection of PCa.12 However, in spite
improvement of the screening test, PCa continues to evidence high
mortality rate in men, especially in US men, ultimately due to
castration-resistant status.12 In the present retrospective study, we
assessed prognostic factors of overall survival and cancer-speciﬁc
survival in patients with mCRPC under docetaxel-based chemo-
therapy as in Western society.
In our institution, we performed four-weekly docetaxel ad-
ministrations of 70 mg/m2 in combination with prednisolone for 5
days from the initiation of every course of chemotherapy.
Compared with Kawahara et al13 who performed chemotherapy of
55 mg/m2 every 3e4 weeks with median overall survival time of
20.1 months, our study did not achieve this length; however, their
study showed a median serum PSA level of 161 ng/mL lower than
that of 386.82 ng/mL in our study. The PSA response in our study,
comprised of 54% of all patients, was associated with better overall
survival and cancer-speciﬁc survival. Some previous studies have
demonstrated a PSA decline of either 30% or 50%, whichmay be
evidence of an early response of a cytotoxic agent with a reduction
of tumor burden, and presents a strong association with
survival.14e16
In Table 2, it shows that the time to PSA nadir was the only
prognostic factor to PSA response compared with those patients
who did not achieve  50% reduction of PSA. Our study suggeststhat longer time to PSA nadir was associated with better PSA
response. The mechanism is not clear, but Thomas et al17 hypoth-
esized that a rapid eradication of chemosensitive tumor cells may
result in strengthening the growth of chemoresistant cells. Ac-
cording to both univariate and multivariate analyses for overall
survival and cancer-speciﬁc survival in patients with mCRPC, time
to PSA nadir also presents a signiﬁcant prognostic factor. The as-
sociation of shorter time to PSA nadir with poorer outcome of
survival has been noted.
The number of cycles of chemotherapy was considered as a
predictor for overall survival. However, the number of cycles the
patients need to receive docetaxel-based chemotherapy is not
conﬁrmed. In our study, ﬁve patients received > 10 cycles of
chemotherapy. Clinically, treatment may continue until adverse
effects occur or disease progression, as in our institution. In a recent
study Pond et al18 found > 10 cycles may not enhance beneﬁts but
exposes more toxicity from retrospective analysis. Therefore, 10
cycles have generally become an acceptable duration of therapy
worldwide. By contrast, in the Nishimura et al19 analysis, selected
patients in Japan showed a favorable response and delayed disease
progression to longer durations of treatment. To prevent fatal
toxicities from docetaxel and concomitant therapy, the condition of
patients must be monitored carefully and regularly prophylactic
drugs can be prescribed before initiation of chemotherapy. In our
multivariate analysis, the longer duration of chemotherapy was
related to higher overall survival and cancer-speciﬁc survival rates.
The result is inconclusive, due to the small sample size. Moreover,
according to our protocol, when the patient lives longer, he will
receive more cycles of chemotherapy if the condition is still stable.
The comorbidity condition in patients may affect survival
outcome and tolerance for toxicities. In order to clarify whether the
comorbidity burden contributes as an independent prognostic
factor for overall survival in mCRPC patients, we used the Charlson
comorbidity index.20 In our study, CCI score was not signiﬁcantly
independent to overall survival and cancer-speciﬁc survival of pa-
tients receiving docetaxel-based chemotherapy, and the result was
the same as the analysis by Goyal et al.20 A previous study still
demonstrated CCI score had no association with overall survival in
patients with locally advanced T3a prostate cancer.21 It is supposed
that the difference in CCI scores between individuals is small in
mCRPC patients, because it is at least six scores with distant
metastases.
PSA level is generally considered to be related to tumor burden;
therefore, PSA progression can present a negative impact to overall
survival for mCRPC patients. As in Hussain et al's22 study, PSA
progression was demonstrated as a signiﬁcant prognostic factor of
survival in patients of CRPC treated with chemotherapy. In our
study, time to PSA progression was shown to be a predictor of
overall survival and cancer-speciﬁc survival, which means longer
time to PSA progression is associated with better survival outcome.
Log-rank p = 0.014
Fig. 2. KaplaneMeier analysis of overall survival according to prostate-speciﬁc antigen (PSA) response status.
Fig. 3. KaplaneMeier analysis of prostate cancer-speciﬁc survival according to prostate-speciﬁc antigen (PSA) response status.
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Table 3
Association of baseline factors with overall survival by univariate and multivariate analysis.
Baseline characteristics Univariate Multivariate
HR 95% C.I. p HR 95% C.I. p
Age (y) 1.011 (0.97, 1.05) 0.592
Number of cycles 0.776 (0.65, 0.92) 0.004* 0.725 (0.60, 0.88) 0.001*
Hemoglobin (g/dL) 0.913 (0.72, 1.15) 0.444
PSA level (ng/mL) 1.000 (1.00, 1.00) 0.563
PSA nadir (ng/mL) 1.001 (1.00, 1.01) 0.416
Time to PSA nadir (m) 0.714 (0.59, 0.87) 0.001* 0.708 (0.57, 0.87) 0.001*
Time to PSA progression (m) 0.915 (0.84, 1.00) 0.038* 0.844 (0.74, 0.96) 0.009*
CCI scores 1.155 (0.92, 1.45) 0.220
* p < 0.05.
CCI ¼ Charlson comorbidity index; CI ¼ conﬁdence interval; HR ¼ hazard ratio; PSA ¼ prostate-speciﬁc antigen.
Table 4
Association of baseline factors with prostate cancer speciﬁc survival by univariate and multivariate analysis.
Baseline characteristics Univariate Multivariate
HR 95% C.I. p HR 95% C.I. p
Age (y) 1.014 (0.97, 1.06) 0.548
Number of cycles 0.773 (0.64, 0.93) 0.005* 0.723 (0.59, 0.88) 0.001*
Hemoglobin (g/dL) 0.884 (0.70, 1.12) 0.312
PSA level (ng/mL) 1.000 (1.00, 1.00) 0.613
PSA nadir (ng/mL) 1.001 (1.00, 1.01) 0.717
Time to PSA nadir (m) 0.711 (0.58, 0.87) 0.001* 0.710 (0.57, 0.88) 0.002*
Time to PSA progression (m) 0.920 (0.84, 1.00) 0.050* 0.849 (0.75, 0.97) 0.014*
CCI scores 1.169 (0.92, 1.49) 0.209
* p < 0.05.
CCI ¼ Charlson comorbidity index; CI ¼ conﬁdence interval; HR ¼ hazard ratio; PSA ¼ prostate-speciﬁc antigen.
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retrospective study with heterogeneous patient backgrounds and a
small sample size. Another is that the included variablesmay not be
complete and lack other potential prognostic factors such as PSA
doubling time, alkaline phosphatase, etc. A future prospective
analysis needs to conﬁrm and validate our results in larger samples
of eligible patients.
5. Conclusion
This study demonstrated that PSA response, cycles of chemo-
therapy, time to PSA nadir, and time to PSA progression could
present predictive factors of overall survival in Taiwanese patients
with mCRPC. However, the CCI did not provide the association. In
addition, time to PSA nadir was longer in PSA response patients
compared with those without PSA response. These signiﬁcant fac-
torsmay take into account the treatment plan and decision-making
after docetaxel-based chemotherapy for mCRPC patients.
Conﬂicts of interest
The authors declare that they have no ﬁnancial or non-ﬁnancial
conﬂicts of interest related to the subject matter or materials dis-
cussed in the manuscript.
Sources of funding
No funding was received for the work described in this article.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:
2893e917.
2. Tseng Chin-Hsiao. Prostate cancer mortality in Taiwanese men: increasing age-
standardized trend in general population and increased risk in diabetic men.
Ann Med 2011;43:142e50.3. Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J. Second-line treatment
options in metastatic castration-resistant prostate cancer: a comparison of key
trials with recently approved agents. Cancer Treat Rev 2014;40:170e7.
4. Saad F, Miller K. Treatment options in castration-resistant prostate cancer:
current therapies and emerging docetaxel-based regimens. Urol Oncol 2014;32:
70e9.
5. Kuramoto T, Inagaki T, Fujii R, Sasaki Y, Nishizawa S, Nanpo Y, et al. Docetaxel
in combination with estramustine and prednisolone for castration-resistant
prostate cancer. Int J Clin Oncol 2013;18:890e7.
6. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al.
Docetaxel and estramustine compared with mitoxantrone and prednisone for
advanced refractory prostate cancer. N Engl J Med 2004;351:1513e20.
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel
plus prednisone or mitoxantrone plus prednisone for advanced prostate can-
cer. N Engl J Med 2004;351:1502e12.
8. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, et al.
Castration-resistant prostate cancer: from new pathophysiology to new
treatment. Eur Urol 2014;65:289e99.
9. Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, et al. Prostate-
speciﬁc antigen changes as surrogate for overall survival in men with meta-
static castration-resistant prostate cancer treated with second-line chemo-
therapy. J Clin Oncol 2013;31:3944e50.
10. Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K, Sumiyoshi Y. Docetaxel-
prednisolone combination therapy for Japanese patients with hormone-
refractory prostate cancer: a single institution experience. Jpn J Clin Oncol
2010;40:1092e8.
11. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with
ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:
1075e9.
12. Petrylak DP. Current state of castration-resistant prostate cancer. Am J Manag
Care 2013;19:s358e65.
13. Kawahara T, Miyoshi Y, Sekiguchi Z, Sano F, Hayashi N, Teranishi J, et al. Risk
factors for metastatic castration-resistant prostate cancer (CRPC) predict long-
term treatment with docetaxel. PLoS One 2012;7:e48186.
14. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-
speciﬁc antigen as a marker of response to cytotoxic therapy for hormone-
refractory prostate cancer. J Clin Oncol 1998;16:1835e43.
15. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara Jr PN, et al.
Evaluation of prostate-speciﬁc antigen declines for surrogacy in patients
treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516e21.
16. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R,
et al. Prostate-speciﬁc antigen and pain surrogacy analysis in metastatic
hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965e70.
17. Thomas BM, Smith C, Evans J, Button MR, Kumar S, Palaniappan N, et al. Time to
prostate speciﬁc antigen (PSA) nadir may predict rapid relapse in men with
metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel
chemotherapy. Med Oncol 2013;30:719.
K.-F. Yang et al. / Urological Science 26 (2015) 271e27627618. Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, et al.
Evaluating the value of number of cycles of docetaxel and prednisone in men
with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363e9.
19. Nishimura K, Nonomura N, Hashine K, Kanayama HO, Ozono S, Miura T, et al.
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for
metastatic castration-resistant prostate cancer: a multicenter, phase II, open-
label, non-comparative,extensionstudy in Japan. Int J ClinOncol2013;18:306e13.
20. Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, et al. Association
of the Charlson comorbidity index and hypertension with survival in menwith metastatic castration-resistant prostate cancer. Urol Oncol 2014;32.
36.e27e34.
21. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Correlations between age,
Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J
Androl 2009;11:131e7.
22. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, et al.
Prostate-speciﬁc antigen progression predicts overall survival in patients with
metastaticprostate cancer: data from Southwest Oncology Group Trials 9346
(Intergroup Study 0162) and 9916. J Clin Oncol 2009;27:2450e6.
